<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ectopic pregnancy: Expectant management of tubal pregnancy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ectopic pregnancy: Expectant management of tubal pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Ectopic pregnancy: Expectant management of tubal pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Togas Tulandi, MD, MHCM, FRCSC, FACOG, FCAHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Courtney A Schreiber, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>An ectopic pregnancy is a pregnancy outside of the uterine cavity. The majority of ectopic pregnancies occur in the fallopian tube, but other possible sites include cervical, interstitial (a pregnancy located in the proximal segment of the fallopian tube that is embedded within the muscular wall of the uterus), intramural, ovarian, or abdominal. Other abnormally implanted pregnancies (eg, hysterotomy [myomectomy, cesarean] scar) can also occur. In addition, in rare cases, a multiple gestation may be heterotopic (include both a uterine and extrauterine pregnancy).</p><p>Ectopic pregnancy is a potentially life-threatening condition, typically requiring expeditious medical or surgical treatment to reduce the risk of rupture of the fallopian tube or another structure and catastrophic hemorrhage. However, in a small proportion of patients for whom the risk of tubal rupture is minimal, expectant management may be offered. Patients who are candidates for expectant management of ectopic pregnancy require informed consent about the risks of this strategy and close observation until the pregnancy has resolved.</p><p>Expectant management of tubal ectopic pregnancy will be reviewed here. Related topics regarding ectopic pregnancy are discussed in detail separately, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Epidemiology, risk factors, and pathology (see  <a class="medical medical_review" href="/z/d/html/5481.html" rel="external">"Ectopic pregnancy: Epidemiology, risk factors, and anatomic sites"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical manifestations and diagnosis (see  <a class="medical medical_review" href="/z/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment (see  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment"</a> and  <a class="medical medical_review" href="/z/d/html/5407.html" rel="external">"Ectopic pregnancy: Methotrexate therapy"</a> and  <a class="medical medical_review" href="/z/d/html/3306.html" rel="external">"Tubal ectopic pregnancy: Surgical treatment"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis and management of uncommon sites of ectopic and abnormally implanted intrauterine pregnancies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abdominal pregnancy (see  <a class="medical medical_review" href="/z/d/html/132045.html" rel="external">"Abdominal pregnancy"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cervical pregnancy (see  <a class="medical medical_review" href="/z/d/html/3283.html" rel="external">"Cervical pregnancy: Diagnosis and management"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cesarean scar pregnancy (see  <a class="medical medical_review" href="/z/d/html/131912.html" rel="external">"Cesarean scar pregnancy"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Heterotopic pregnancy (see  <a class="medical medical_review" href="/z/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis", section on 'Heterotopic pregnancy'</a> and  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment", section on 'Heterotopic pregnancy'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Interstitial pregnancy (see  <a class="medical medical_review" href="/z/d/html/5407.html" rel="external">"Ectopic pregnancy: Methotrexate therapy", section on 'Patients with an interstitial pregnancy: Multiple-dose'</a> and  <a class="medical medical_review" href="/z/d/html/3306.html" rel="external">"Tubal ectopic pregnancy: Surgical treatment", section on 'Interstitial pregnancy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with pregnancy of unknown location (see  <a class="medical medical_review" href="/z/d/html/134770.html" rel="external">"Approach to the patient with pregnancy of unknown location"</a>)</p><p></p><p class="headingAnchor" id="H2898305577"><span class="h1">PATIENT SELECTION</span><span class="headingEndMark"> — </span>The most common treatments of tubal ectopic pregnancy are pharmacologic therapy with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) or surgical treatment; only a small proportion of patients are candidates for expectant management  (<a class="graphic graphic_algorithm graphicRef114571" href="/z/d/graphic/114571.html" rel="external">algorithm 1</a>). How to choose between these treatment options is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment"</a>.)</p><p>Candidates for expectant management include patients with <strong>all</strong> of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>No symptoms (eg, abdominal pain) or signs of impending or ongoing ectopic mass rupture (eg, evidence of hemoperitoneum on ultrasound).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Confirmed or suspected tubal ectopic pregnancy on transvaginal ultrasound (TVUS); findings may include (see  <a class="medical medical_review" href="/z/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A complex inhomogeneous extraovarian adnexal mass.</p><p></p><p class="bulletIndent2">An extrauterine mass that is characterized as not being suspicious for an ectopic pregnancy (eg, corpus luteum) is not included in this category. (See  <a class="medical medical_review" href="/z/d/html/5410.html" rel="external">"Ultrasonography of pregnancy of unknown location"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An extraovarian adnexal mass containing an empty gestational sac.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An extrauterine gestational sac with a yolk sac or embryo (<strong>without</strong> a heartbeat).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum quantitative beta-human chorionic gonadotropin (hCG) concentration is low (eg, ≤200 milli-international units [mIU]/mL) and decreasing [<a href="#rid1">1</a>]. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment", section on 'Medical versus expectant management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Understand the clinical implications and risks of an ectopic pregnancy and tubal rupture. (See <a class="local">'Outcomes'</a> below and  <a class="medical medical_review" href="/z/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis", section on 'Natural history'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ready access to a medical facility that can provide emergency surgical treatment, if needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient prefers expectant management rather than MTX or surgical treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Able and willing to comply with close follow-up.</p><p></p><p>These criteria are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment"</a> and  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment", section on 'Medical versus expectant management'</a>.)</p><p class="headingAnchor" id="H736054241"><span class="h1">CLINICAL PROTOCOL</span><span class="headingEndMark"> — </span>Human chorionic gonadotropin (hCG) levels are followed every two days for three measurements to confirm that the hCG levels continue to decrease (eg, decrease of &gt;10 percent across two consecutive measurements), and then weekly until undetectable. Ultrasound is repeated only as clinically necessary (eg, new or worsening symptoms) and is <strong>not</strong> needed to confirm pregnancy resolution [<a href="#rid2">2</a>]. Patients must be advised to use reliable contraception during the entire period of hCG monitoring. A new pregnancy during this time makes it difficult to interpret hCG results and complicates management.</p><p>Expectant management is <strong>abandoned</strong> in patients with a plateau or increase in hCG levels (increase of &gt;10 percent across two consecutive measurements) or those with increasing abdominal pain. Such patients require surgery or medical therapy. (See  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment", section on 'Choosing between methotrexate and surgery'</a>.):</p><p>Patients with hCG levels that are decreasing, but more slowly than expected (eg, decrease of &lt;10 percent), may be offered treatment with MTX or continuation of expectant management. In our practice, we treat such patients with MTX; we also offer MTX to those patients in whom hCG levels have not reach undetectable within 10 weeks. (See  <a class="medical medical_review" href="/z/d/html/5407.html" rel="external">"Ectopic pregnancy: Methotrexate therapy", section on 'Preferred approach for most patients: Single-dose'</a>.)</p><p class="headingAnchor" id="H1242761739"><span class="h1">OUTCOMES</span></p><p class="headingAnchor" id="H3714911822"><span class="h2">Resolution of ectopic pregnancy</span><span class="headingEndMark"> — </span>Successful expectant management of ectopic pregnancy is defined as reaching an undetectable level of human chorionic gonadotropin (hCG; &lt;5 to 10 milli-international units [mIU]/mL at most laboratories) without complications or conversion to a treatment method (ie, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [MTX], surgery). Success rates vary widely, in part due to differences in inclusion criteria [<a href="#rid1">1,3-6</a>]. </p><p>Several randomized trials have evaluated expectant management of ectopic pregnancy and have demonstrated success rates comparable to MTX therapy [<a href="#rid1">1,3,7-10</a>] . However, the level of evidence is low to moderate given low sample size, relatively low (median) hCG levels, and differing protocols used for medical management included in these studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In one trial including 80 patients with tubal ectopic pregnancy and serum hCG <em>&lt;</em>1500 mIU/mL (median hCG: 405 to 465 mIU/mL), patients receiving placebo or MTX (50 mg/m<sup>2</sup> intramuscular [IM]) had similar rates of uneventful decline of hCG and time to pregnancy resolution (14 to 18 days [median]); patients with embryonic heartbeat or hemoperitoneum were excluded from the study [<a href="#rid7">7</a>]. The rate of surgical intervention was lower with MTX compared with placebo (17 versus 24 percent), and failure rate in patients with a baseline hCG 1000 to 1500 mIU/mL was also lower in the MTX group (38 versus 67 percent), but the study lacked sufficient statistical power to detect these differences. The risk of failure was significantly impacted by hCG level in both groups, with the risk increasing by 0.12 percent for each unit increase in hCG. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another trial including 15 patients with a confirmed ectopic pregnancy and a plateauing hCG &lt;1500 mIU/mL (median hCG: 535 and 708 mIU/mL), patients receiving expectant management or MTX (1 mg/kg body weight IM with a maximum of 100 mg) had similar rates of uneventful declines of hCG and hCG clearance times; patients with a viable ectopic pregnancy, signs of tubal rupture, and/or active intraabdominal bleeding were excluded from the study [<a href="#rid3">3</a>]. There were no tubal ruptures or serious complications. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other small randomized trials also found comparable success rates for MTX and placebo [<a href="#rid1">1,8</a>]. In one trial including 60 patients with ectopic pregnancy, low-dose (2.5 mg) oral MTX was used for the treatment group [<a href="#rid1">1</a>]. For comparison, therapeutic doses for rheumatoid arthritis are typically at least 15 mg orally per day. Thus, it is not surprising that both groups had similar outcomes.</p><p></p><p>Prospective studies show similar results. In a literature review of studies including 700 patients with ectopic pregnancy undergoing expectant management, 69 percent of patients experienced ectopic pregnancy resolution [<a href="#rid4">4</a>]. In a subsequent prospective study including 177 patients with ectopic pregnancy managed expectantly, resolution of the ectopic pregnancy by ultrasound occurred two weeks after hCG normalization in 63 percent of patients; longer resolution times (&gt;78 days) occurred in 4.5 percent of patients [<a href="#rid11">11</a>]. There was a positive correlation between resolution time and initial hCG level.</p><p class="headingAnchor" id="H1419214499"><span class="h2">Tubal rupture</span><span class="headingEndMark"> — </span>Tubal rupture can occur in any patient with ectopic pregnancy, even those with low and declining hCG levels [<a href="#rid12">12</a>]. </p><p>There are few data to determine the threshold hCG level that allows for expectant management of ectopic pregnancy without unnecessary risk of tubal rupture. In a population-based study including 843 patients with ectopic pregnancy, tubal rupture occurred in 18 percent rate of patients; patients treated with MTX and those with pregnancy of unknown location were excluded from the study [<a href="#rid13">13</a>]. For comparison, rates of rupture after MTX treatment are 7 to 14 percent [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment", section on 'Outcomes'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Subsequent reproductive function</span><span class="headingEndMark"> — </span>Patients with ectopic pregnancy who are managed expectantly appear to have similar subsequent reproductive outcomes as those managed medically or surgically, but data are limited. In a prospective study including 30 patients with ectopic pregnancy managed expectantly, subsequent hysterosalpingography demonstrated tubal patency of the affected tube in 93 percent of cases [<a href="#rid15">15</a>]. The subsequent intrauterine pregnancy rate was 88 percent, and one patient (4 percent) had an ectopic pregnancy. Other studies have reported intrauterine pregnancy rates between 63 and 84 percent of patients [<a href="#rid15">15-18</a>]. </p><p class="headingAnchor" id="H3626179015"><span class="h1">CONSIDERATIONS FOR FUTURE PREGNANCY</span><span class="headingEndMark"> — </span>The safe interval from resolution of ectopic pregnancy to conception of another pregnancy is unclear and there are no studies addressing the earliest time to conceive after expectant management of ectopic pregnancy. We advise patients that they may try to conceive again following their next menstrual period. </p><p>As with all patients with a history of ectopic pregnancy, subsequent pregnancies should be monitored closely with serial measurement of human chorionic gonadotropin (hCG) levels and early transvaginal ultrasound. We use the same clinical protocol as for patients with a pregnancy of unknown location and start with the first missed menses or after embryo transfer for those undergoing in vitro fertilization. The goal is to establish the diagnosis early and avoid tubal rupture. (See  <a class="medical medical_review" href="/z/d/html/134770.html" rel="external">"Approach to the patient with pregnancy of unknown location", section on 'Hemodynamically stable patients'</a>.)</p><p class="headingAnchor" id="H3707044356"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118506.html" rel="external">"Society guideline links: Ectopic pregnancy"</a>.)</p><p class="headingAnchor" id="H3192702422"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15856.html" rel="external">"Patient education: Ectopic pregnancy (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/6723.html" rel="external">"Patient education: Ectopic (tubal) pregnancy (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H8"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical context</strong> – Ectopic pregnancy is a potentially life-threatening condition typically requiring expeditious medical or surgical treatment  (<a class="graphic graphic_algorithm graphicRef114571" href="/z/d/graphic/114571.html" rel="external">algorithm 1</a>). However, in a small proportion of patients in whom the risk of tubal rupture is minimal, expectant management may be an option. How to choose between these treatment options is discussed in detail separately. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection</strong> – Candidates for expectant management should have <strong>all</strong> of the following (see <a class="local">'Patient selection'</a> above and  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No symptoms (eg, abdominal pain) or signs of impending or ongoing ectopic mass rupture. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Confirmed or suspected tubal ectopic pregnancy on transvaginal ultrasound (TVUS); findings may include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A complex inhomogeneous extraovarian adnexal mass</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>An extraovarian adnexal mass containing an empty gestational sac</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>An extrauterine gestational sac with a yolk sac or embryo (<strong>without</strong> a heartbeat)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum quantitative beta-human chorionic gonadotropin (hCG) concentration is low (eg, ≤200 milli-international units [mIU]/mL) and decreasing. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Understand the clinical implications and risks of an ectopic pregnancy and tubal rupture. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ready access to a medical facility that can provide emergency surgical treatment, if needed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patient prefers expectant management rather than <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [MTX] or surgical treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Able and willing to comply with close follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical protocol</strong> – hCG levels are followed every 48 hours for three measurements to confirm that the hCG level continues to decline, and then weekly until it is undetectable. Ultrasound is repeated only as clinically necessary (eg, new or worsening symptoms) and is not needed to confirm pregnancy resolution. (See <a class="local">'Clinical protocol'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who experience a plateau or increase in hCG levels or have increasing abdominal pain, expectant management is abandoned; these patients require definitive treatment for ectopic pregnancy (ie, with surgery or MTX), as appropriate for the clinical situation. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/112852.html" rel="external">"Ectopic pregnancy: Choosing a treatment", section on 'Choosing between methotrexate and surgery'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For asymptomatic patients who are managed expectantly and have hCG levels that are declining, but more slowly than expected (eg, decrease of &lt;10 percent or not yet undetectable by 10 weeks), we suggest treatment with MTX rather than continuation of expectant management (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Resolution</strong> – Success rates (ie, reaching an undetectable level of hCG) of expectant management appear to be similar to MTX therapy. (See <a class="local">'Resolution of ectopic pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tubal rupture</strong> – Tubal rupture can occur in any patient with ectopic pregnancy, even those with low and declining hCG levels. The threshold hCG level that allows for expectant management of ectopic pregnancy without unnecessary risk of tubal rupture is uncertain. (See <a class="local">'Tubal rupture'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subsequent pregnancy</strong> – Patients with ectopic pregnancy who are managed expectantly appear to have similar subsequent reproductive outcomes as those managed medically or surgically, but data are limited. (See <a class="local">'Subsequent reproductive function'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Future pregnancy</strong> – We advise patients that they may try to conceive again following their next menstrual period. As with all patients with a history of ectopic pregnancy, subsequent pregnancies should be monitored closely with serial measurement of hCG levels and early TVUS. (See <a class="local">'Considerations for future pregnancy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Korhonen J, Stenman UH, Ylöstalo P. Low-dose oral methotrexate with expectant management of ectopic pregnancy. Obstet Gynecol 1996; 88:775.</a></li><li><a class="nounderline abstract_t">Brown WW. Ultrasound Diagnosis: Ectopic Pregnancy. Topics in Obstetrics &amp; Gynecology 2010; 30.</a></li><li><a class="nounderline abstract_t">van Mello NM, Mol F, Verhoeve HR, et al. Methotrexate or expectant management in women with an ectopic pregnancy or pregnancy of unknown location and low serum hCG concentrations? A randomized comparison. Hum Reprod 2013; 28:60.</a></li><li><a class="nounderline abstract_t">Craig LB, Khan S. Expectant management of ectopic pregnancy. Clin Obstet Gynecol 2012; 55:461.</a></li><li><a class="nounderline abstract_t">Kirk E, Condous G, Bourne T. The non-surgical management of ectopic pregnancy. Ultrasound Obstet Gynecol 2006; 27:91.</a></li><li><a class="nounderline abstract_t">van Mello NM, Mol F, Adriaanse AH, et al. The METEX study: methotrexate versus expectant management in women with ectopic pregnancy: a randomised controlled trial. BMC Womens Health 2008; 8:10.</a></li><li><a class="nounderline abstract_t">Jurkovic D, Memtsa M, Sawyer E, et al. Single-dose systemic methotrexate vs expectant management for treatment of tubal ectopic pregnancy: a placebo-controlled randomized trial. Ultrasound Obstet Gynecol 2017; 49:171.</a></li><li><a class="nounderline abstract_t">Silva PM, Araujo Júnior E, Cecchino GN, et al. Effectiveness of expectant management versus methotrexate in tubal ectopic pregnancy: a double-blind randomized trial. Arch Gynecol Obstet 2015; 291:939.</a></li><li><a class="nounderline abstract_t">Colombo GE, Leonardi M, Armour M, et al. Efficacy and safety of expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis. Hum Reprod Open 2020; 2020:hoaa044.</a></li><li><a class="nounderline abstract_t">Solangon A, Van Wely M, Van Mello N, et al. Methotrexate versus expectant management for treatment of tubal ectopic pregnancy: An individual participant data meta-analysis (IPD-MA). Hum Reprod 2022; 37:i379.</a></li><li><a class="nounderline abstract_t">Dooley W, De Braud L, Memtsa M, et al. Physical resolution of tubal ectopic pregnancy on ultrasound imaging following successful expectant management. Reprod Biomed Online 2020; 40:880.</a></li><li><a class="nounderline abstract_t">Tulandi T, Hemmings R, Khalifa F. Rupture of ectopic pregnancy in women with low and declining serum beta-human chorionic gonadotropin concentrations. Fertil Steril 1991; 56:786.</a></li><li><a class="nounderline abstract_t">Job-Spira N, Fernandez H, Bouyer J, et al. Ruptured tubal ectopic pregnancy: risk factors and reproductive outcome: results of a population-based study in France. Am J Obstet Gynecol 1999; 180:938.</a></li><li><a class="nounderline abstract_t">Bachman EA, Barnhart K. Medical management of ectopic pregnancy:  a comparison of regimens. Clin Obstet Gynecol 2012; 55:440.</a></li><li><a class="nounderline abstract_t">Rantala M, Mäkinen J. Tubal patency and fertility outcome after expectant management of ectopic pregnancy. Fertil Steril 1997; 68:1043.</a></li><li><a class="nounderline abstract_t">Zohav E, Gemer O, Segal S. Reproductive outcome after expectant management of ectopic pregnancy. Eur J Obstet Gynecol Reprod Biol 1996; 66:1.</a></li><li><a class="nounderline abstract_t">Strobelt N, Mariani E, Ferrari L, et al. Fertility after ectopic pregnancy. Effects of surgery and expectant management. J Reprod Med 2000; 45:803.</a></li><li><a class="nounderline abstract_t">Helmy S, Sawyer E, Ofili-Yebovi D, et al. Fertility outcomes following expectant management of tubal ectopic pregnancy. Ultrasound Obstet Gynecol 2007; 30:988.</a></li></ol></div><div id="topicVersionRevision">Topic 5455 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8885912" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Low-dose oral methotrexate with expectant management of ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Ultrasound Diagnosis: Ectopic Pregnancy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23081873" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Methotrexate or expectant management in women with an ectopic pregnancy or pregnancy of unknown location and low serum hCG concentrations? A randomized comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22510629" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Expectant management of ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16374758" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The non-surgical management of ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18565217" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The METEX study: methotrexate versus expectant management in women with ectopic pregnancy: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27731538" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Single-dose systemic methotrexate vs expectant management for treatment of tubal ectopic pregnancy: a placebo-controlled randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25315383" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effectiveness of expectant management versus methotrexate in tubal ectopic pregnancy: a double-blind randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33134560" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Efficacy and safety of expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Methotrexate versus expectant management for treatment of tubal ectopic pregnancy: An individual participant data meta-analysis (IPD-MA)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32414664" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Physical resolution of tubal ectopic pregnancy on ultrasound imaging following successful expectant management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1717319" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Rupture of ectopic pregnancy in women with low and declining serum beta-human chorionic gonadotropin concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10203662" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ruptured tubal ectopic pregnancy: risk factors and reproductive outcome: results of a population-based study in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22510626" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Medical management of ectopic pregnancy:  a comparison of regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9418694" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Tubal patency and fertility outcome after expectant management of ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8735750" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Reproductive outcome after expectant management of ectopic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11077627" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Fertility after ectopic pregnancy. Effects of surgery and expectant management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18044813" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Fertility outcomes following expectant management of tubal ectopic pregnancy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
